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Introduction
The differentiation of skeletal muscle is a complex multi-step
process involving events that bring about proliferation of myoblast
progenitor cells, withdrawal of these cells from the cell cycle,
commitment to a myogenic phenotype and subsequent
differentiation into the multinucleate syncytia, of which mature
muscle cells are comprised (reviewed by Anderson, 1998; Grounds,
1991; Lluis et al., 2006). Although much is known about the
transcriptional control of the myogenic process, and the signalling
pathways involved (Chun et al., 2000; Perdiguero et al., 2007a;
Perdiguero et al., 2007b), there is still much to be understood about
how these events are initiated and controlled.
The caspases comprise a family of cysteine proteases and some
members of the family are responsible for causing apoptosis. Of
these, caspase-3, caspase-6 and caspase-7 are classed as ‘effectors’,
cleaving a wide range of intracellular proteins and being responsible
for causing many of the changes typical of apoptosis (Alnemri, 1997;
Salvesen, 2002). Effectors are expressed as zymogens and are
activated when cleaved by ‘initiator’ caspases such as caspase-8
and caspase-9. Initiators are also expressed as zymogens but are
activated by recruitment into large multi-protein complexes.
Different apoptotic signals activate different initiators, but all the
initiators activate a common set of effectors. Thus, during apoptosis,
different pro-apoptotic signals are integrated and amplified through
a proteolytic cascade of initiator and effector caspase activity that
kills the cell (Boatright and Salvesen, 2003; Shi, 2004; Slee et al.,
1999).
It is therefore remarkable that the apoptotic effector caspase,
caspase-3, not only appears to be required for the differentiation of
muscle progenitor cells into myofibres but apparently is sufficient
for this differentiation (Fernando et al., 2002). It is unknown how
caspase-3 is activated during differentiation and therefore we
investigated how caspase-3 was activated during this process to test
whether a non-apoptotic or an apoptotic pathway is involved. To
accomplish this we used the C2C12 mouse myoblast cell line. These
mononuclear cells fuse into multinucleate myotubes under low-
serum conditions and, hence, are a useful model in which to study
the events during muscle differentiation.
We show that caspase-3 activation and myotube formation is
inhibited by a reduction of caspase-9 expression or by Bcl-xL
overexpression, showing the involvement in myoblastic
differentiation of two genes that are normally involved in the
mitochondrial apoptotic pathway. These data are important because
they show that two genes that usually regulate and/or control
commitment to apoptosis can be employed for the very different
purpose of myoblastic differentiation.
Results
Suppression of myoblast differentiation using a broad-
spectrum caspase inhibitor
Previous research has shown that caspase-3 has a role in skeletal-
muscle formation, demonstrating a transient increase in caspase-3-
like activity associated with myoblastic differentiation (Fernando
et al., 2002). Using the C2C12 mouse myoblast cell line, we sought
to confirm these findings by culturing the cells in low-serum-
containing media.
When C2C12 cells are induced to differentiate, a proportion of
the cells undergo apoptosis rather than becoming myoblasts
(Huppertz et al., 2001). To study caspase activity during
differentiation it is therefore important to ensure that assays for
caspase activation and caspase activity were not influenced by the
presence of apoptotic cells. An early event of apoptosis is the
Caspases, a family of cysteine proteases most often investigated
for their roles in apoptosis, have also been demonstrated to have
functions that are vital for the efficient execution of cell
differentiation. One such role that has been described is the
requirement of caspase-3 for the differentiation of skeletal
myoblasts into myotubes but, as yet, the mechanism leading to
caspase-3 activation in this case remains elusive. Here, we
demonstrate that caspase-9, an initiator caspase in the
mitochondrial death pathway, is responsible for the activation
of caspase-3 in differentiating C2C12 cells. Reduction of
caspase-9 levels, using an shRNA construct, prevented caspase-
3 activation and inhibited myoblast fusion. Myosin-heavy-
chain expression, which accompanies myoblastic differentiation,
was not caspase-dependent. Overexpression of Bcl-xL, a protein
that inhibits caspase-9 activation, had the same effect on muscle
differentiation as knockdown of caspase-9. These data suggest
that the mitochondrial pathway is required for differentiation;
however, the release of cytochrome c or Smac (Diablo) could
not be detected, raising the possibility of a novel mechanism of
caspase-9 activation during muscle differentiation.
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3787Caspase-9-dependent myotube formation
detachment of cells from the substratum and we observed that some
cells (<10%) detached from the culture plate during differentiation.
The nuclear morphology of these floating cells was apoptotic, as
assessed by DAPI staining (Fig. 1A). To minimise the effect of any
apoptotic cells on our experiments, we washed our plates extensively
to remove non-adherent cells before analysing caspase activity in
differentiating cultures. DAPI staining showed the nuclear
morphology of the adherent cells (Fig. 1A) and that >99.8% of these
cells had normal nuclear morphology.
The activity of caspase-3 in adherent C2C12 cells was assessed
next. Induction of differentiation in C2C12 resulted in an increase
in caspase-3-like activity (DEVDase activity) in adherent cells over
a 5-day differentiation time course (Fig. 1B). The activity was
transient, being clearly detectable by 12 hours (data not shown) and
achieving maximal activity (~600 AFU/minute/mg) at 48 hours.
By comparison, the activity in C2C12 cells that were treated with
staurosporine (both adherent and detached cells) was 1100
AFU/minute/mg and approximately 25% of the cells were apoptotic
in staurosporine-treated cultures. Activation of caspase-3 involves
proteolytic processing of the pro-form to smaller subunits, an event
that is detectable by immunoblot (Fig. 1C). Processing of the 32-
kD pro-form of caspase-3 was seen to follow a similar profile to
the caspase-3-like activity over the time course, with the appearance
of the p17 form detectable by 3-6 hours (data not shown) and
maximal detection at 48 hours (Fig. 1C). Thus, two independent
assays demonstrate that caspase-3 is activated upon induction of
myoblast differentiation.
In order to test the functional role of caspase-3 in myoblast
differentiation, a broad-spectrum caspase inhibitor, Q-VD-OPH
(Caserta et al., 2003) was added to the cells prior to induction of
differentiation. Addition of 30 μM Q-VD-OPH significantly inhibited
caspase-3-like (DEVDase) activity (Fig. 2A) and caspase-3 processing
(data not shown) over the 5-day period in comparison with untreated
controls. Two differentiation-related phenotypes were assayed at each
time point to assess the effect on differentiation into myotubes: the
appearance of myosin heavy chain (MyHC) (Fig. 2B) and the number
of cell-fusion events. Cell fusion was severely impaired by the
inhibitor (Fig. 2C). Despite a reduction in cell fusion, Q-VD-OPH
had a much lesser effect on the elongation of the myoblasts into
spindle-shaped cells and the expression of MyHC, changes normally
occurring prior to myotube formation (Fig. 2B).
If the caspase inhibitor increased the number of cells in the culture
by blocking apoptosis, but these rescued cells were unable to
differentiate, the conclusion that Q-VD-OPH inhibited fusion would
be incorrect. Therefore, the number of cells per field was determined
in both inhibitor-treated and untreated controls, and found to be no
different (Fig. 2D). This excludes skewing of the data that could
be attributable to cytoprotective effects of the inhibitor.
Thus, caspase-3 is required for efficient cell fusion during
myoblast differentiation, findings that are consistent with an earlier
report (Fernando et al., 2002). However, it is unknown how
caspase-3 is activated in differentiating cells and we therefore set
out to test whether apoptotic or non-apoptotic pathways were
involved.
Two major caspase-activation pathways that drive apoptosis have
been characterized; the death-receptor pathway, in which caspase-
8 is the initiator caspase (Peter and Krammer, 2003), and the
mitochondrial pathway, in which caspase-9 is the initiator caspase
(Riedl and Salvesen, 2007). To test which initiator caspases were
involved in myoblastic differentiation, the activation of caspase-1
caspase-2, caspase-8 and caspase-9 were assessed by immunoblot
to detect caspase processing. Initiators caspase-1, caspase-2 and
caspase-8 showed neither a decrease in the pro-form nor the
appearance of a cleavage product over the differentiation time course
(data not shown). By contrast, blotting for initiator caspase-9
revealed its processing from the 48-kDa pro-form to the 35- and
37-kDa forms (Fig. 3A). This processing was also accompanied by
the appearance of caspase-3 activity, making caspase-9 a strong
candidate for the initiator caspase that is activated during myoblast
differentiation.
Caspase processing, however, is not a certain indicator of caspase
activity so, in order to obtain evidence of caspase-9 activation, we
performed affinity labelling using z-VAD–fmk–biotin (Faleiro et
al., 1997; Tu et al., 2006). Cells were incubated in growth or
differentiation medium containing biotinylated caspase inhibitor for
12 hours, after which cells were lysed and labelled caspases
purified using streptavidin beads. Labelled caspases were then
detected by immunoblotting. The whole-cell lysates (input samples)
showed that 37- and 35-kDa processing products of caspase-9 were
detectable. Caspase-9 processing was similar in cells cultured in
growth medium or differentiation medium, most probably because,
at 12 hours, the differentiation process is just beginning, making
detection of increased processing more difficult. However, caspase-
9 was only labelled by the inhibitor in cells incubated in
differentiation medium, showing that caspase-9 was active only
under differentiation conditions (Fig. 3B). Whereas caspase-9
processing resulted in more of the 35-kDa species than the 37-kDa
species (Fig. 3A), the 37-kDa form was labelled more than the 35-
Fig. 1. Non-apoptotic morphology of adherent C2C12 cells and caspase-3
activity in the adherent cells. C2C12 cells were induced to differentiate over a
5-day time course. (A) DAPI-stained nuclear morphology of adherent and
detached C2C12 cells after 2 days of differentiation. (B) Caspase-3-like
activity was assayed using the fluorogenic substrate DEVD-afc over a 5-day
differentiation period. Enzyme activity is expressed as an increase in arbitrary
fluorescent units per minute per milligram of protein (AFU/min/mg). The
histogram shows the mean ± s.d. of three independent experiments.
(C) Immunoblot for caspase-3 processing over a 5-day differentiation period.
Staurosporine-treated (1 μM for 4 hours) C2C12 cells (+ve) were used as a
positive control for caspase-3 cleavage.
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kDa form. This is consistent with the report that the 37-kDa form
has eightfold higher protease activity than the 35-kDa form (Zou
et al., 2003). Caspase-1, caspase-2 and caspase-8 were not labelled
(data not shown), making these caspases poor candidates for the
role of initiator caspase during myoblast differentiation.
shRNA-mediated knockdown of caspase-9
If caspase-9 is the initiator caspase during myoblast differentiation,
then prevention of caspase-9 activation or activity is predicted to have
the same effect on differentiation as inhibition of caspase-3 activity.
To test the importance of caspase-9 in myoblast differentiation, we
reduced caspase-9 levels in C2C12 cells using adenoviral (Ad)-vector-
mediated delivery of a small hairpin RNA (shRNA) construct against
murine caspase-9 (McDonnell et al., 2003). The construct was
delivered at an MOI of 2500 to C2C12 cultures at 24 hours prior to
the induction of differentiation using low-serum media. Within 2 days
of transduction (day 1 of differentiation), caspase-9 expression was
reduced to approximately 50% of normal expression levels (Fig. 4A),
with a further reduction in expression over the subsequent 2 days.
The knockdown was specific in that no reduction in expression levels
of caspase-2, caspase-3 or caspase-8 was detectable (data not shown).
Expression and processing of caspases-3 and caspase-9 were also
unaffected in control differentiated cells, which were transduced with
AdNull vector, containing no transgene, or a nonsense-shRNA Ad
vector (Fig. 4A and data not shown) at the same MOI. The delivery
Journal of Cell Science 121 (22)
of AdNull and nonsense vectors also excluded the possibility that
interferon-induced changes altered differentiation patterns.
Delivery of caspase-9 shRNA resulted in a significant reduction
of caspase-3-like activity (DEVDase) in the cells (Fig. 4B).
Furthermore, caspase-9 and caspase-3 processing was inhibited (Fig.
4C). A profound decrease in myoblast fusion was seen following
caspase-9 knockdown (Fig. 4D), whereas cell fusion to form
myotubes was unaffected by delivery of an AdNull vector or
nonsense-RNA Ad vector (Fig. 4E and data not shown). Thus,
caspase-9 is required for caspase-3 activation and efficient cell
fusion during myoblast differentiation
Bcl-xL overexpression in C2C12 myoblasts
If caspase-9 is initiating caspase-3 activation, it is possible that the
mitochondrial pathway activated during apoptosis is serving a very
different role in myoblast differentiation. The mitochondrial
pathway is inhibited by anti-apoptotic proteins of the Bcl-2 family
(van Delft and Huang, 2006). Therefore, in order to test the role of
the mitochondrial pathway in muscle-cell differentiation, an Ad
vector was designed to overexpress Bcl-xL, which inhibits the
activation of caspase-9 by preventing cytochrome c release from
mitochondria (Jurgensmeier et al., 1998).
Prior to induction of differentiation, cells were transduced with
an adenoviral vector encoding Bcl-xL (AdBcl-Xl; Fig. 5A) at an
MOI of 250. Control cells were transduced, at the same MOI, with
Fig. 2. A caspase inhibitor impairs differentiation. A broad-
spectrum pharmacological caspase inhibitor, Q-VD-OPH, was
used at 30 μM to inhibit caspase activity in differentiating
C2C12 cells. Cells were incubated in differentiation media for
the indicated time, and caspase-activity assays were conducted
and MyHC expression analysed. The histograms show the mean
± s.d. of three independent experiments. (A) Caspase-3-like
activity in differentiating C2C12 cells in the presence (grey) or
absence (black) of 30 mM Q-VD-OPH. Enzyme activity is
expressed as an increase in arbitrary fluorescent units per
minute per milligram of protein (AFU/min/mg). (B) MyHC
(green) expression during differentiation with DNA
counterstaining with Hoechst 33342 (blue). (C) The degree of
muscle-cell differentiation was determined by scoring cell
fusion (see Materials and Methods). (D) The number of nuclei
per field was determined for each treatment.Jo
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an AdNull vector, produced by deletion of the Bcl-xL gene from
the construct. Transduction with Bcl-xL vector resulted in a
significant reduction in DEVDase activity, in comparison with
AdNull-transduced cells, at 1 day, 2 days and 3 days after induction
of muscle differentiation (Fig. 5B). Caspase-3 and caspase-9
processing, which peaked at day 2 in the AdNull-transduced cells,
in a manner very similar to non-transduced differentiating
myoblasts, was abolished in the cells overexpressing Bcl-xL (Fig.
5C). Bcl-xL expression was shown to attenuate myotube formation
and the number of fusion events was significantly reduced in
comparison with control cells (Fig. 5D,E). As with the caspase
inhibitor, possible skewing of fusion-event results owing to
cytoprotective effects of Bcl-xL was ruled out by ensuring that the
total nuclei numbers per well were not significantly different
between AdBcl-xL-transduced cells and those transduced with
AdNull (data not shown).
MyHC expression
Not all changes associated with differentiation were affected by
caspase inhibition. MyHC is not expressed in myoblasts but its
expression increases as these cells differentiate. At early time points
during differentiation, mononucleate MyHC-expressing cells were
observed, indicating that MyHC expression was not dependent on
cell fusion. At later time points the number of nuclei per MyHC-
expressing cell was seen to be increased in a caspase-dependent
manner (Fig. 6A) as the myoblasts fused to form myotubes. However,
the average number of MyHC-expressing cells was not significantly
affected by Q-VD-OPH treatment, Bcl-xL expression or caspase-9
shRNA expression (Fig. 6B), showing that MyHC expression was
not caspase dependent. The current data do not reveal whether MyHC
expression is upstream of caspase-dependent changes or part of an
independent, parallel pathway during differentiation.
Fig. 3. Caspase-9 is activated during differentiation. (A) Caspase-9 processing
was detected by immunoblotting over a 5-day differentiation time course.
Staurosporine-treated (1 μM for 4 hours) C2C12 cells (+ve) were used as a
positive control for caspase cleavage. (B) Affinity labelling of the 37-kDa band
of processed caspsase-9. C2C12 cells were cultured for 12 hours in growth
media (GM) or differentiation media (DM) in the presence or absence of
50 μM biotin-VAD-fmk. Labelled caspases were affinity purified and detected
by immunoblot.
Fig. 4. shRNA against caspase-9 impairs muscle differentiation.
C2C12 cells were transduced with either an adenoviral vector
encoding shRNA targeted against caspase-9 (AdshRNA-C9) or the
same vector without the shRNA (AdNull). Caspase-9 levels were
assessed by immunoblot (A) and the effect of shRNA on caspase-3-
like activity was assessed by DEVD-afc (B). Enzyme activity is
expressed as an increase in arbitrary fluorescent units per minute per
milligram of protein (AFU/min/mg). (C) The effect of AdshRNA-
C9 knockdown on caspase processing was determined by
immunoblot. Arrows indicate the processed forms of caspase-9 and
caspase-3. (D) The effect of AdshRNA-C9 knockdown on cell
fusion (see Materials and Methods) was assessed. The histograms
show the mean ± s.d. of three separate experiments. (E) Top,
western blot for caspase-9 in stained samples. Bottom, MyHC
(green) staining with DNA (blue) counterstaining (Hoechst 33342).
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Apoptotic mitochondrial events during muscle differentiation
The dependence of differentiation on caspase-9 and the inhibition
of differentiation by Bcl-xL suggest that the mitochondrial pathway
that is normally associated with apoptosis is being activated in
differentiating cells and that this event is required for cell fusion.
To test this idea we investigated whether the pro-apoptotic molecules
cytochrome c and Smac (also known as Diablo) were released from
mitochondria in differentiating cells and whether the mitochondrial
membranes of these cells depolarized during differentiation.
To assess the release of cytochrome c and Smac, cell lysates from
differentiating cells were prepared, followed by the preparation of
cytoplasmic and mitochondrial fractions. Immunoblotting showed
that, whereas an apoptotic stimulus (staurosporine) triggered the
release of both these proteins, release of cytochrome c and Smac
was not detectable in differentiating cells (Fig. 7A).
Activation of the mitochondrial pathway during apoptosis is also
associated with mitochondrial-membrane depolarisation (Bossy-
Wetzel et al., 1998). To test whether depolarisation occurred during
differentiation of C2C12 cells, cells were stained with TMRE and
changes in mitochondrial membrane potential assessed by flow
cytometry (Fig. 7C). Whereas staurosporine induced an obvious
depolarisation of mitochondrial membranes, no depolarisation was
seen in differentiating cells, despite the high levels of caspase
activity that were associated with differentiation.
Thus, although the effects of Bcl-xL overexpression and caspase-
9 shRNA implicate the mitochondrial pathway in differentiation,
we found no direct evidence of mitochondrial changes occurring
in the differentiating cells.
Discussion
The process of myoblast fusion within the musculature is a complex
one and, although much is known about the transcription factors
involved, and which signalling pathways are implicated, the process
that allows the extensive reassembly of cytoplasmic and membrane
components of the cell is poorly understood. Fernando et al.
(Fernando et al., 2002) provided evidence that an apoptotic caspase,
caspase-3, was required for skeletal myoblast differentiation, and
research on the effects of apoptosis repressor with caspase
recruitment domain (ARC) on cardiac-muscle fusion has suggested
a role for caspase-3 in cardiomyocyte differentiation (Hunter et al.,
2007). Although these results clearly implicate the effector caspase
in differentiation, neither report identified components of the
pathway that are responsible for caspase-3 activation. Here, we set
out to resolve whether caspase-3 was activated during differentiation
by an apoptotic pathway or a specific differentiation pathway.
Our data show that an initiator caspase, caspase-9, is activated
in differentiating cells and is required for caspase-3 activation and
cell fusion. Several lines of evidence support the conclusion that
caspase-9 is the initiator of caspase activation during myoblast
differentiation. First, its processing shows a similar temporal profile
to that of caspase-3, suggesting that it might be responsible for
activating caspase-3. By contrast, the processing of other known
apoptotic initiator caspases, caspase-1, caspase-2 and caspase-8, was
not detectable. We have not excluded a role for the other mouse
initiator, caspase-12, which might have importance in this process,
given the effect of endoplasmic reticulum (ER) stress on myoblast
differentiation (Nakanishi et al., 2007). Second, the processing of
caspase-9 suggests autocatalytic proteolysis, consistent with
caspase-9 being the initiator. Autocatalytic processing of caspase-
9 generates p35 and p12 subunits, which together form a tetramer,
(p35/p12)2, which activates caspase-3 (Zou et al., 2003). The p37
Fig. 5. Bcl-xL overexpression impairs differentiation. C2C12 cells were
transduced with either an adenoviral vector encoding the anti-apoptotic protein
Bcl-xL (AdBcl-xL) or with the same vector without the transgene (AdNull).
Bcl-xL expression was assessed by immunoblot (A) and caspase-3-like
activity was assayed using DEVD-afc (B). Enzyme activity is expressed as an
increase in arbitrary fluorescent units per minute per milligram of protein
(AFU/min/mg). The effect of Bcl-xL expression on caspase processing (C) and
on MyHC expression (D) was assessed by immunoblot and
immunohistochemistry. MyHC is shown in green whereas DNA
counterstaining (Hoechst 33342) is shown in blue. (E) The degree of muscle-
cell differentiation was determined as before (see Materials and Methods). The
histograms show mean + s.d. of three separate experiments.
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subunit and p10 subunits of caspase-9 are generated when caspase-
3 cleaves caspase-9 in a positive-feedback loop. During
differentiation, caspase-9 was processed to generate the p35 and
p37 subunits, with p35 being the major product (the p12 and p10
subunits are not detectable with the antibody used). Finally,
reduction of caspase-9 levels with a specific shRNA prevented
caspase-3 activation. These findings are consistent with a model in
which muscle differentiation requires caspase-9 as the initiator of
caspase-3 activity.
Caspase-9 is the initiator of the mitochondrial or intrinsic
apoptotic pathway and this pathway is controlled by members of
the Bcl-2 family. We found that overexpression of Bcl-xL
compromised differentiation in the same way as reduction of
caspase-9 protein using shRNA technology. Together, these data
suggest that caspase-3 is activated through the mitochondrial
apoptotic pathway during muscle differentiation 
However, our investigation of apoptotic mitochondrial events in
differentiating cells did not reveal detectable cytochrome c release,
Smac release or mitochondrial depolarisation and these data are
inconsistent with activation of the mitochondrial pathway. Thus, it
is possible that some other caspase-9-dependent, Bcl-xL-sensitive
pathway is involved. Interestingly, primary myoblasts are known
to undergo caspase-9-dependent but Apaf1-independent apoptosis
(Ho et al., 2004) and, during this apoptosis, caspase-9 is processed
to both the p37 and p35 forms (Ho et al., 2007). Although these
data raise the possibility of a novel caspase-9 activator in muscle
cells, the Apaf1-independent apoptosis requires Smac release from
mitochondria (Ho et al., 2007), which is an event that we cannot
detect in differentiating cells. Because the mitochondrial pathway
is dependent on Apaf1, we attempted to reduce Apaf1 expression
by shRNA-based approaches in C2C12 cells. However, we failed
to consistently and significantly reduce Apaf1 expression and, at
this time, we can neither implicate nor exclude a role for Apaf1 in
muscle differentiation.
Studies from caspase-3 and caspase-7 double-knockout mice
suggest a different explanation that reconciles a role for caspase-9
and Bcl-xL; no detectable mitochondrial events occurred in these
mice. Lakhani et al. (Lakhani et al., 2006) have suggested a positive-
feedback mechanism in the mitochondrial pathway; this mechanism
involves very low levels of cytochrome c release triggering caspase-
3 activation, which subsequently induces the large, rapid release of
cytochrome c that is associated with apoptosis. There is also a
potential role for the involvement of BH3-only proteins during
muscle differentiation (Shaltouki et al., 2007), because p53 both
regulates myotube formation (Porrello et al., 2000) and expression
of BH3-only proteins such as Noxa and Puma. This raises the
possibility that these ‘killer’ proteins have broader functions than
currently suspected.
Although all of the strategies that we employed to manipulate
caspase activity and activation had very profound effects on caspase
activity, cell fusion was only delayed and not abolished. These data
suggest the existence of redundant caspase-dependent and 
-independent pathways for cell fusion. This implies that more than
one pathway is activated in parallel and that either can induce
myotube formation. The protease calpain might be part of this
caspase-independent pathway because it is known to be important
in myotube formation (Balcerzak et al., 1995; Temm-Grove et al.,
1999) and shares some substrates with caspases (Vanags et al.,
Fig. 6. Number of MyHC-expressing cells per field. C2C12 cells were induced to differentiate after the indicated treatments, then harvested and fixed in graded
methanol. Fixed cells were immunostained for MyHC expression. The number of nuclei per MyHC-positive cell (A) and the number of MyHC-positive cells per
microscopical field (B) were scored. The histograms show the mean ± s.d. of three independent experiments. *P=0.005.
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1996). Other markers of cell differentiation, besides cell fusion, such
as myogenin expression, were minimally affected by caspase
inhibition (data not shown) or, similar to MyHC expression, were
not affected at all. Thus, it is clear that caspase activity plays an
important but restricted role in the differentiation process.
Our findings have important implications for the fields of cell
death, differentiation and muscle disease. Signals leading to caspase-
3 activation are usually considered to commit a cell to death. The
data shown here confirm that caspase-3 activity can be harnessed
for differentiation, and add to our understanding by showing that
caspase-3 is activated by a caspase-9-dependent and Bcl-xL-sensitive
process. Thus, caspase-3 and caspase-9 are not just agents of cellular
disassembly but help decide the fate of differentiating myoblasts.
Discovery of which caspase substrates are cleaved in differentiating
myoblasts and which are not will be key to understanding how these
cells survive the activation of the intrinsic apoptotic pathway and
use this pathway to complete myotube formation.
Materials and Methods
Myoblast cell culture and differentiation protocol
C2C12 myoblasts (ECACC) were maintained in culture and induced to undergo
differentiation as previously described (Fernando et al., 2002).
Journal of Cell Science 121 (22)
Caspase-activity assay
Caspase activity was assayed as previously described (Martin and Fearnhead, 2002).
Enzyme activity was expressed as arbitrary fluorescence units per minute per mg of
protein (AFU/minute/mg).
Affinity labelling active caspase-9
Cells were treated with 50 μM biotinylated VAD-fmk for 12 hours in either their
normal growth medium or differentiation medium. Cell extracts were prepared as
previously described (Faleiro et al., 1997). The extracts were subsequently incubated
with streptavidin-conjugated sepharose beads for 2 hours at 4°C. The beads were
then washed four times with high-salt PBS (400 mM NaCl) before being resuspended
in Laemmli loading buffer and heated to 95°C. The proteins were separated by SDS-
PAGE and caspase-9 detected by immunoblotting.
Adenoviral vector production and transduction
The AdBcl-xL and AdNull adenoviral vectors were generated, propagated and purified
as described before (Fallaux et al., 1996; Ritter et al., 1999). The AdshRNA-C9 and
AdshRNA-eGFP vectors were generated using the ViraPower adenovirus expression
system (Invitrogen). They encoded shRNA constructs targeted against the caspase-
9 and jellyfish enhanced green fluorescent protein (eGFP) genes, respectively, under
the control of the human U6 promoter (Behrend et al., 2005; Zwacka et al., 1998).
shRNA sense and antisense oligos were synthesized to target a 21-nucleotide
sequence within the mouse caspase-9 sequence (5-AAGCAGGA T -
CCAGAGGCTGTT-3) as described (McDonnell et al., 2003).
For all viral transductions, cells were seeded at 2.5104 cells/cm2 in 24-well plates
and cultured overnight in growth medium before being transduced with the viral
vectors for a further overnight incubation. The medium was then changed to
differentiation medium.
Immunoblotting
Briefly, the cells were lysed and protein concentrations determined by Bradford assay
to ensure equal protein loading in gels. The primary antibodies used were against
caspase-3 (Cell Signaling, 1:1000), caspase-9 (Cell Signaling, 1:1000), β-actin (Cell
Signaling, 1:1000), COX IV (Cell Signaling, 1:1000), cytochrome c (BD Bioscience,
1:1000) and Smac (Adrain et al., 2001). Bound primary antibodies were visualised
using chemiluminescence detection of HRP-labelled secondary antibodies (Pierce,
1:5000) and a CCD camera.
Cell fractionation
Cells were collected by centrifugation (350 g, 5 minutes, 4°C) and resuspended in
100 μl of ice-cold lysis buffer (80 mM KCl, 250 mM sucrose and 200 μg/ml digitonin
in PBS). The samples were incubated on ice for 5 minutes and then centrifuged at
10,000 g for 5 minutes at 4°C. The recovered pellet and supernatant were then assayed
by immunoblot for the release of mitochondrial-intermembrane-space proteins.
Mitochondrial-membrane depolarisation
To detect changes in mitochondrial-membrane potential (ΔΨm), cells were stained
with tetramethylrhodamine ethyl ester perchlorate (TMRE; Molecular Probes) (Farkas
et al., 1989). Briefly, 1106 cells/sample were plated and treated appropriately, after
which time samples were collected and washed where appropriate. The samples were
then resuspended at 2106 cells/ml in growth medium containing 10 μM TMRE for
30 minutes at 37°C. They were then pelleted, washed once in DMEM, resuspended
in DMEM at 1106 cells/ml and analysed by flow cytometry.
Immunocytochemistry
Briefly, cells were washed in PBS, fixed in graded concentrations of methanol and
stained as previously described (Megeney et al., 1996). MyHC MF20 mAb
(Development Studies Hybridoma Bank, 1:100) was detected with FITC-conjugated
anti-mouse IgG Alexa-Fluor-488 (Invitrogen, 1:200) and nuclei were stained with
Hoechst 33342 (2 μg/ml).
Quantification of muscle-cell differentiation
The degree of muscle-cell differentiation was determined by a fusion-event scoring
system. The percentage number of fusion events was calculated in ten random
microscope fields using the following formula:
% fusion events = [(NM-M)/NT]100,
where NM=number of nuclei in MyHC-positive cells, M=number of MyHC-positive
cells and NT=total number of nuclei.
Counts were verified by two independent observers.
We thank Gerry Cohen of the MRC Toxicology Unit, Kevin Sullivan,
NUI Galway and Dominic Wells of Imperial College, London for
comments and advice; Peter Dockery of NUIG for aid with microscopy;
and Tina Harte for help with adenoviral vector preparation. This work
Fig. 7. Mitochondrial changes in apoptotic but not differentiating cells. C2C12
cells were treated with staurosporine (+ve) to induce apoptosis or were
induced to differentiate. Differentiating cultures were washed to remove non-
adherent cells. Cells were then harvested, lysed and centrifuged to obtain
cytosolic and mitochondrial subcellular fractions. (A) The presence of
mitochondrial proteins in the cytosolic fractions was then detected by
immunoblotting. (B) Mitochondrial contamination of subcellular fractions was
assessed by immunoblotting for COX IV. The results shown are typical of
three independent experiments. (C,D) Alternatively, cells were harvested and
stained with TMRE to detect Δψm by flow cytometry. The results shown are
typical of three independent experiments.
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